07:56 AM EDT, 04/29/2025 (MT Newswires) -- Profound Medical ( PROF ) on Tuesday said initial peri-operative data from a trial comparing the safety and efficacy of the company's TULSA procedure with radical prostatectomy showed "significantly" superior post-treatment patient experience compared to robotic prostatectomy.

According to a statement, the data showed that patients who underwent the TULSA procedure to remove diseased tissue experienced zero blood less, reduced post-procedure pain and and strong improvement in mobility.

The trial was conducted in men with organ-confined, intermediate-risk prostate cancer and the results were presented on Monday at the American Urological Association meeting in Las Vegas. As at January, 201 men were randomized and, to-date, 194 have been treated or scheduled for treatment.